Each study has a usefulness score out of 100 (rubric version 4.0). Tap a score to see what makes it up.
Download bibliography of all 5,209 studies, highest score first: BibTeX (.bib) · RIS (.ris)
Highest usefulness score first. Studies without a score come last.
-
The proposed approach achieves 97.9% AD Classification Index (ADCI) for the Kaggle dataset and 97.9% ADCI for the MIRIAD dataset.
Why it matters
This study describes a classifier called Alzheimer-net that achieved high accuracy in detecting Alzheimer's disease from brain MRI images on two datasets. These results are about diagnostic classification performance and do not address treating, curing, or preventing the disease.
-
Alzheimer's disease is a neurological illness that impacts mental and emotional functions functions, has become a global concern due to its increasing prevalence.
Why it matters
This study used machine learning algorithms, including transformer techniques, to explore early detection of Alzheimer disease, with the Random Forest algorithm achieving the highest accuracy of 98.9%. The findings are expected to contribute to more accurate and efficient early detection strategies, but the study does not report a treatment or cure.
-
Alzheimer's Disease acts as a degenerative brain trauma that results in poor memory, alongside impairing mental functioning.
Why it matters
This study built a web-based system using a custom convolutional neural network to sort brain MRI scans into Mild Demented, Moderate Demented, Very Mild Demented and Non-Demented categories, reporting 88.5% accuracy. It is a diagnostic classification tool only and does not test any treatment, cure or prevention.
-
The results may contribute to refining current diagnostic techniques, promoting earlier detection, and assisting in the development of advanced tools for accurate brain tumor diagnosis and treatment planning.
Why it matters
This work uses deep learning to detect Alzheimer's and brain tumors, and its results may help refine diagnostic techniques and promote earlier detection. It does not report any treatment, cure, or prevention of Alzheimer's disease.
-
28/100
Alzheimer's disease is a neurodegenerative disorder affecting millions globally, with early detection being critical for effective management.
Why it matters
Optimized neural networks detected Alzheimer's disease from MRI scans with 86.25% accuracy for a compact MobileNetV2 model and 91.56% for an ensemble, while reducing model size by 75-77%. This is a diagnostic screening tool study, not a treatment, cure, or prevention.
-
Este trabalho é uma revisão de literatura que explora a relação entre mecanismos epigenéticos e a Doença de Alzheimer (DA), uma doença neurodegenerativa caracterizada por perda de memória e dificuldades cognitivas.
Why it matters
This literature review describes how epigenetic mechanisms such as DNA methylation and microRNAs may affect genes related to amyloid plaques, neurofibrillary tangles, and APOE in Alzheimer disease. The authors state that the study of epigenetics in Alzheimer disease is still incipient and more research is needed, so no treatment, cure, or prevention is established.
-
Alzheimer's disease, AD, has been a difficult problem for relevant experts and patients since its discovery.
Why it matters
This review describes how amyloid plaques and tau tangles are important causes of Alzheimer disease and notes that most current treatments only relieve cognitive decline, while monoclonal antibody drugs against plaques have drawbacks such as insufficient efficacy or serious side effects. It concludes there is still a lack of treatment for patients with more severe symptoms.
-
Study 1 was designed for 8 weeks with weekly 3D6.IgG2a injections, but was aborted after the first injection when 7/10 mice died within 36 hours.
Why it matters
In this mouse study, most mice given the anti-Abeta antibody 3D6.IgG2a died within 36 hours, and surviving treated brains showed surface macro-hemorrhages while controls had no visible bleeds. The authors propose a mouse strain as a possible model for studying ARIA, but this is animal research and provides no treatment or cure for patients.
-
Alzheimer’s disease (AD) is a progressive neurological condition that leads to dementia.
Why it matters
This study describes a deep learning model that classified Alzheimer's disease stages from MRI images with high accuracy. These results are about diagnostic classification and do not address treating, curing, or preventing the disease.
-
Biomarkers in cerebrospinal fluid (CSF) are being used increasingly to diagnose early Alzheimer's disease (AD).
Why it matters
This report describes how a cerebrospinal fluid profile based on the ratio of Ab1-42 to total tau is used to diagnose early Alzheimer's disease, and notes that this profile was often present in patients with subjective complaints and mild cognitive impairment and predicted decline in cognition and daily function. It concerns diagnosis and prognosis only, with no treatment, cure, or prevention tested.
-
In human brain extracts, most proteins of pathological interest in Alzheimer's disease are insoluble and their analysis is often performed on denatured and reduced samples by immunoblotting after electrophoresis on polyacrylamide gel in presence of sodium dodecyl sulfate.
Why it matters
This 1989 laboratory study compared protein measurement methods in brain extracts and found an 8- to 16-fold GFAP increase and two pathological Tau variants in Alzheimer brains. It is a methods and tissue analysis study and does not provide any treatment, cure, or prevention for Alzheimer's disease.
-
27/100
A Doença de Alzheimer (DA) é uma patologia neurodegenerativa de caráter progressivo, marcada pela deterioração gradual das funções cognitivas e motoras do indivíduo, com o consequente comprometimento da memória, da linguagem e do comportamento.
Why it matters
This Brazilian review describes the clinical and epidemiological picture of Alzheimer's disease, noting higher prevalence in women and rising incidence in Brazil over the last 10 years. It is a descriptive review of secondary data and does not test any treatment, cure, or prevention.
-
Alzheimer's disease is a multifactorial neurodegenerative disorder characterized by amyloid- β aggregation, oxidative stress, neuroinflammation, tau hyperphosphorylation, and cholinergic dysfunction.
Why it matters
This review of chalcone derivatives describes how chemical modifications affect activity against Alzheimer-related targets such as AChE, BuChE, MAO-B, and amyloid. It states that translation is limited by insufficient in vivo validation and pharmacokinetic constraints, so no treatment or cure is established.
-
These findings support the use of triazole scaffolds as a unique and versatile framework for developing multifunctional anti‐Alzheimer agents with perceived disease‐modifying activity.
Why it matters
This review discusses triazole-based compounds that inhibit acetylcholinesterase, butyrylcholinesterase, MAO and BACE1, with some structure-activity studies showing marked inhibition and perceived neuroprotective activity. It is a chemistry review and does not report clinical benefit in patients.
-
One of the biggest health issues of the twenty-first century is Alzheimer's disease (AD), which is the most prevalent cause of dementia.
Why it matters
This review describes existing drugs like memantine and cholinesterase inhibitors that only relieve symptoms without changing the course of the disease. It notes that newer anti-amyloid antibodies such as aducanumab and lecanemab have raised cautious optimism but that concerns about accessibility and safety remain.
-
Resumen Introducción La vía amiloidogénica de procesamiento de la proteína precursora del amiloide es bien conocida a nivel de patogenia y terapéutica en la enfermedad de Alzheimer (EA), mientras que la vía no-amiloidogénica ha sido menos estudiada.
Why it matters
ADAM10 is the main α-secretase in the non-amyloidogenic pathway and is implicated in Alzheimer's pathogenesis, but genetic studies have not found causal variants in cohorts. Stimulating ADAM10 is a therapeutic possibility, with only one positive clinical trial using the retinoid acitretin so far.
-
Alzheimer’s disease is the leading cause of dementia and represents a growing global health challenge.
Why it matters
This review describes how advanced glycation end-products accumulate with age and are found in senile plaques and neurofibrillary tangles, where they can promote amyloid aggregation and tau hyperphosphorylation. It is a review of mechanisms only and does not report any treatment, cure, or prevention tested in patients.
-
Dysregulated ferritinophagy-mediated ferroptosis is a pivotal AD pathogenic target.
Why it matters
This review proposes that dysregulated ferritinophagy-mediated ferroptosis is a pathogenic target in Alzheimer's disease and outlines unresolved questions and future research directions. It calls for validation in models and clinical specimens and for development of specific modulators, so no treatment or cure is yet available.
-
Alzheimer disease (AD) is a progressive neurodegenerative disease and the most common cause of dementia in the world, which has a gradual deterioration of memory, thinking and autonomy.
Why it matters
This review describes mechanisms proposed for Alzheimer's disease, including amyloid-beta aggregation, tau hyperphosphorylation, neuroinflammation, and genetic factors such as APOE 4. It mentions that treatment has moved toward disease-modifying approaches such as anti-amyloid monoclonal antibodies and anti-tau therapy, but reports no new trial results or cure.
-
Alzheimer disease (AD) is the neurodegenerative condition that occurs in the elderly population above 65 years old and is the major cause of dementia.
Why it matters
This review states that currently FDA-available drugs for Alzheimer's disease can decrease symptoms but not prevent the disease. It lists emerging approaches such as anti-amyloid antibodies, anti-tau therapies, stem cell and gene therapies, and plant compounds, but presents no confirmed cure or prevention.
-
Alzheimer's disease (AD) is a neurodegenerative disorder involving the amyloid-β plaque deposition, tau pathology, synaptic dysfunction, and impairment in cognition.
Why it matters
In experimental Alzheimer's models, curcumin-loaded polymeric nanoparticles improved cognitive test performance compared with free curcumin and reduced amyloid plaque burden with preserved neuronal architecture. These are animal and histopathological findings, so they do not establish a treatment or cure for people.
-
However, knowledge alone does not consistently predict screening behavior.
Why it matters
This review found that primary care physicians' knowledge of Alzheimer's symptoms and screening tools does not consistently predict whether they screen patients. It does not address treating, curing, or preventing Alzheimer's disease.
-
Alzheimer disease involves interacting mechanisms that include amyloid-beta accumulation, abnormal tau phosphorylation and aggregation, cholinergic dysfunction, synaptic degeneration, neuronal loss, neuroinflammation, vascular pathology, and genetic susceptibility.
Why it matters
This narrative review describes Alzheimer's disease as a multifactorial condition involving many interacting mechanisms, with increasing age as the main risk factor. It notes that current management includes cholinesterase inhibitors, memantine, behavioral and lifestyle measures, and emerging amyloid-targeting therapies.
-
This article tells us how modern biotechnology and AI are redefining Alzheimer’s disease through early detection, advanced biomarkers, and innovative treatments like lecanemab.
Why it matters
This review describes how biomarkers and imaging can enable prevention measures to be taken early, and how treatment includes ChEIs, memantine, and anti-amyloid antibodies such as lecanemab and donanemab. It states that new biotechnologies like gene editing, stem cells, nanotech, and AI are helping scientists better understand and treat Alzheimer's disease, though it reports no new trial results.
-
A Doença de Alzheimer (DA) constitui um dos maiores desafios de saúde pública devido ao seu impacto crescente na população idosa, especialmente em razão do aumento da expectativa de vida.
Why it matters
This review confirms that the APOE ε4 allele is the main genetic risk factor for late-onset Alzheimer disease, while ε2 has a protective effect. It notes that environmental, biological, and population factors significantly modify the impact of these variants, but it does not report a new treatment or cure.
From across this topic
10 of the 5,172 studies in this topic, picked by a fixed rule (a hash of each study's address), not by score or date; each page of this list shows a different 10. The same 10 appear here every time.
- Duration of preclinical, prodromal, and dementia stages of Alzheimer's disease in relation to age, sex, and APOE genotype
- Astrocyte activation imaging with 11C-acetate and amyloid PET in mild cognitive impairment due to Alzheimer pathology
- Sleep duration, genetic susceptibility, and Alzheimer's disease: a longitudinal UK Biobank-based study
- A survey on various Alzheimer classification techniques using 3D MRI images: a challenging overview
- Temporal Correlation of CSF and Neuroimaging in the Amyloid-Tau-Neurodegeneration Model of Alzheimer Disease
- Retinal biomarkers in cognitive impairment and dementia: Structural, functional, and molecular insights
- Cognitive outcomes after sertaline treatment in patients with depression of Alzheimer disease
- Early and late change on the preclinical Alzheimer's cognitive composite in clinically normal older individuals with elevated amyloid β
- GBA and APOE Impact Cognitive Decline in Parkinson's Disease: A 10-Year Population-Based Study
- Lecanemab, Donanemab, and Emerging Disease Modifying Therapies for Alzheimer Disease: Clinical Evidence and Primary Care Implications in Canada